NASDAQ:ALLK

Allakos Stock Forecast, Price & News

$79.56
-1.94 (-2.38 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$79.40
$82.77
50-Day Range
$76.53
$101.44
52-Week Range
$73.75
$157.98
Volume292,872 shs
Average Volume272,967 shs
Market Capitalization$4.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.9
30 days | 90 days | 365 days | Advanced Chart
Receive ALLK News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.


Allakos logo

About Allakos

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.36 out of 5 stars

Medical Sector

97th out of 842 stocks

Pharmaceutical Preparations Industry

42nd out of 324 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Allakos (NASDAQ:ALLK) Frequently Asked Questions

Is Allakos a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allakos stock.
View analyst ratings for Allakos
or view top-rated stocks.

What stocks does MarketBeat like better than Allakos?

Wall Street analysts have given Allakos a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allakos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Allakos
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) issued its earnings results on Sunday, May, 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.18.
View Allakos' earnings history
.

How has Allakos' stock been impacted by COVID-19 (Coronavirus)?

Allakos' stock was trading at $58.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALLK stock has increased by 36.5% and is now trading at $79.56.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ALLK?

6 analysts have issued 12-month price targets for Allakos' stock. Their forecasts range from $76.53 to $230.00. On average, they expect Allakos' share price to reach $167.38 in the next year. This suggests a possible upside of 110.4% from the stock's current price.
View analysts' price targets for Allakos
or view top-rated stocks among Wall Street analysts.

Who are Allakos' key executives?

Allakos' management team includes the following people:
  • Robert Alexander, Chief Executive Officer & Director
  • Adam L. Tomasi, President & Chief Operating Officer (LinkedIn Profile)
  • Harlan Baird Radford, Chief Financial Officer
  • Craig Paterson, Chief Medical Officer
  • Ruby Casareno, Vice President-Technical Operations

Who are some of Allakos' key competitors?

What other stocks do shareholders of Allakos own?

When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (1.08%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Veracity Capital LLC (0.00%) and Cutler Group LP (0.00%). Company insiders that own Allakos stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander and Robert J More.
View institutional ownership trends for Allakos
.

Which institutional investors are selling Allakos stock?

ALLK stock was sold by a variety of institutional investors in the last quarter, including Veracity Capital LLC. Company insiders that have sold Allakos company stock in the last year include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, and Robert J More.
View insider buying and selling activity for Allakos
or view top insider-selling stocks.

Which institutional investors are buying Allakos stock?

ALLK stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and Zurcher Kantonalbank Zurich Cantonalbank .
View insider buying and selling activity for Allakos
or or view top insider-buying stocks.

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $79.56.

How much money does Allakos make?

Allakos has a market capitalization of $4.26 billion. The company earns $-153,480,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

How many employees does Allakos have?

Allakos employs 141 workers across the globe.

What is Allakos' official website?

The official website for Allakos is www.allakos.com.

Where are Allakos' headquarters?

Allakos is headquartered at 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 597-5002 or via email at [email protected]


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.